Bayer (FRA:BAYN) has been assigned a €86.00 ($100.00) target price by stock analysts at Berenberg Bank in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s price target points to a potential upside of 14.82% from the company’s previous close.
Several other analysts have also commented on BAYN. JPMorgan Chase & Co. set a €75.00 ($87.21) price objective on Bayer and gave the company a “neutral” rating in a report on Monday, January 6th. UBS Group set a €110.00 ($127.91) price objective on Bayer and gave the company a “buy” rating in a report on Tuesday, November 19th. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the company a “buy” rating in a report on Friday, October 25th. Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer and gave the company a “buy” rating in a report on Monday. Finally, Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the company a “neutral” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of €79.94 ($92.95).
Shares of BAYN opened at €74.90 ($87.09) on Tuesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98). The stock has a fifty day moving average price of €71.61 and a 200-day moving average price of €66.01.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.